I. Emerman

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials”.

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.04.007

N/A

0.347DataRank · unranked

5 citations

Edith T. Zemanick, Michael W. Konstan, Clement L. Ren, Katherine Odem‐Davis, I. Emerman +3 more

117 Maternal and fetal outcomes in the era of CFTR modulators (MAYFLOWERS) study: interim results

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01051-2

N/A

0DataRank · unranked

1 citations

I. Emerman, P. Vu, Noël Cameron, Ashley Keller, Alexandra Wilson +3 more

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.02.001

N/A

0DataRank · unranked

26 citations

I. Emerman, Morgan McCreary, N. Mayer-Hamblett, Mark N. Warden, Katherine Odem‐Davis +5 more